Browsing by title

Now showing items 21-40 of 4758

    • 5-fraction radiotherapy for breast cancer: FAST Forward to implementation. 

      Somaiah, N; Brunt, AM; Haviland, JS; Kirby, AM; Wheatley, D; Bliss, J; Yarnold, JR

    • 5-fraction radiotherapy for breast cancer: FAST Forward to implementation. 

      Somaiah, N; Brunt, AM; Haviland, JS; Kirby, AM; Wheatley, D; Bliss, J; Yarnold, JR

    • 6p abnormalities and TNF-α over-expression in retinoblastoma cell line 

      Imbert, I; Coignet, LJA; Pellestor, F (2001)
      Retinoblastoma is the most common primary intra-ocular tumor in childhood. It has been established that recurrent cytogenetic abnormalities are the hallmark of mostly all malignant tumors. Recurrent atypical cytogenetic ...

    • 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors. 

      Bavetsias, V; Lanigan, RM; Ruda, GF; Atrash, B; McLaughlin, MG; Tumber, A; Mok, NY; Le Bihan, Y-V; Dempster, S; Boxall, KJ; Jeganathan, F; Hatch, SB; Savitsky, P; Velupillai, S; Krojer, T; England, KS; Sejberg, J; Thai, C; Donovan, A; Pal, A; Scozzafava, G; Bennett, JM; Kawamura, A; Johansson, C; Szykowska, A; Gileadi, C; Burgess-Brown, NA; von Delft, F; Oppermann, U; Walters, Z; Shipley, J; Raynaud, FI; Westaway, SM; Prinjha, RK; Fedorov, O; Burke, R; Schofield, CJ; Westwood, IM; Bountra, C; Müller, S; van Montfort, RLM; Brennan, PE; Blagg, J (2016-02)
      We report the discovery of N-substituted 4-(pyridin-2-yl)thiazole-2-amine derivatives and their subsequent optimization, guided by structure-based design, to give 8-(1H-pyrazol-3-yl)pyrido[3,4-d]pyrimidin-4(3H)-ones, a ...

    • 90 YEARS OF PROGESTERONE: Progesterone receptor signaling in the normal breast and its implications for cancer. 

      Brisken, C; Scabia, V (2020-07)
      Progesterone is considered as the pregnancy hormone and acts on many different target tissues. Progesterone receptor (PR) signaling is important for normal development and the physiologic function of the breast and impinges ...

    • A Big Bang model of human colorectal tumor growth. 

      Sottoriva, A; Kang, H; Ma, Z; Graham, TA; Salomon, MP; Zhao, J; Marjoram, P; Siegmund, K; Press, MF; Shibata, D; Curtis, C (2015-03)
      What happens in early, still undetectable human malignancies is unknown because direct observations are impractical. Here we present and validate a 'Big Bang' model, whereby tumors grow predominantly as a single expansion ...

    • A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. 

      Bruna, A; Rueda, OM; Greenwood, W; Batra, AS; Callari, M; Batra, RN; Pogrebniak, K; Sandoval, J; Cassidy, JW; Tufegdzic-Vidakovic, A; Sammut, S-J; Jones, L; Provenzano, E; Baird, R; Eirew, P; Hadfield, J; Eldridge, M; McLaren-Douglas, A; Barthorpe, A; Lightfoot, H; O'Connor, MJ; Gray, J; Cortes, J; Baselga, J; Marangoni, E; Welm, AL; Aparicio, S; Serra, V; Garnett, MJ; Caldas, C (2016-09-15)
      The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-clinical models. We have created a large collection of breast cancer patient-derived tumor xenografts (PDTXs), in which the ...

    • A biomarker model of sublethal genotoxicity (DNA single-strand breaks and adducts) using the sentinel organism Aporrectodea longa in spiked soil 

      Martin, FL; Piearce, TG; Hewer, A; Phillips, DH; Semple, KT (ELSEVIER SCI LTD, 2005-11)
      There is a need to develop risk biomarkers during the remediation of contaminated land. We employed the earthworm, Aporreetodea longa (Ude), to determine whether genotoxicity measures could be applied to this organism’s ...

    • A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients. 

      Sadanandam, A; Bopp, T; Dixit, S; Knapp, DJHF; Emperumal, CP; Vergidis, P; Rajalingam, K; Melcher, A; Kannan, N (2020-12-08)
      COVID-19 patients show heterogeneity in clinical presentation and outcomes that makes pandemic control and strategy difficult; optimizing management requires a systems biology approach of understanding the disease. Here ...

    • A Canadian approach to the regionalization of testis cancer: A review. 

      Nason, GJ; Wood, LA; Huddart, RA; Albers, P; Rendon, RA; Einhorn, LH; Nichols, CR; Kollmannsberger, C; Anson-Cartwright, L; Sweet, J; Warde, P; Jewett, MAS; Chung, P; Bedard, PL; Hansen, AR; Hamilton, RJ (2020-10)
      At the Canadian Testis Cancer Workshop, the rationale and feasibility of regionalization of testis cancer care were discussed. The two-day workshop involved urologists, medical and radiation oncologists, pathologists, ...

    • A case-control study of risk of leukaemia in relation to mobile phone use. 

      Cooke, R; Laing, S; Swerdlow, AJ (2010-11)
      Background Mobile phone use is now ubiquitous, and scientific reviews have recommended research into its relation to leukaemia risk, but no large studies have been conducted.Methods In a case-control study in South East ...

    • A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. 

      Coignard, J; Lush, M; Beesley, J; O'Mara, TA; Dennis, J; Tyrer, JP; Barnes, DR; McGuffog, L; Leslie, G; Bolla, MK; Adank, MA; Agata, S; Ahearn, T; Aittomäki, K; Andrulis, IL; Anton-Culver, H; Arndt, V; Arnold, N; Aronson, KJ; Arun, BK; Augustinsson, A; Azzollini, J; Barrowdale, D; Baynes, C; Becher, H; Bermisheva, M; Bernstein, L; Białkowska, K; Blomqvist, C; Bojesen, SE; Bonanni, B; Borg, A; Brauch, H; Brenner, H; Burwinkel, B; Buys, SS; Caldés, T; Caligo, MA; Campa, D; Carter, BD; Castelao, JE; Chang-Claude, J; Chanock, SJ; Chung, WK; Claes, KBM; Clarke, CL; GEMO Study Collaborators; EMBRACE Collaborators; Collée, JM; Conroy, DM; Czene, K; Daly, MB; Devilee, P; Diez, O; Ding, YC; Domchek, SM; Dörk, T; Dos-Santos-Silva, I; Dunning, AM; Dwek, M; Eccles, DM; Eliassen, AH; Engel, C; Eriksson, M; Evans, DG; Fasching, PA; Flyger, H; Fostira, F; Friedman, E; Fritschi, L; Frost, D; Gago-Dominguez, M; Gapstur, SM; Garber, J; Garcia-Barberan, V; García-Closas, M; García-Sáenz, JA; Gaudet, MM; Gayther, SA; Gehrig, A; Georgoulias, V; Giles, GG; Godwin, AK; Goldberg, MS; Goldgar, DE; González-Neira, A; Greene, MH; Guénel, P; Haeberle, L; Hahnen, E; Haiman, CA; Håkansson, N; Hall, P; Hamann, U; Harrington, PA; Hart, SN; He, W; Hogervorst, FBL; Hollestelle, A; Hopper, JL; Horcasitas, DJ; Hulick, PJ; Hunter, DJ; Imyanitov, EN; KConFab Investigators; HEBON Investigators; ABCTB Investigators; Jager, A; Jakubowska, A; James, PA; Jensen, UB; John, EM; Jones, ME; Kaaks, R; Kapoor, PM; Karlan, BY; Keeman, R; Khusnutdinova, E; Kiiski, JI; Ko, Y-D; Kosma, V-M; Kraft, P; Kurian, AW; Laitman, Y; Lambrechts, D; Le Marchand, L; Lester, J; Lesueur, F; Lindstrom, T; Lopez-Fernández, A; Loud, JT; Luccarini, C; Mannermaa, A; Manoukian, S; Margolin, S; Martens, JWM; Mebirouk, N; Meindl, A; Miller, A; Milne, RL; Montagna, M; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Nielsen, FC; O'Brien, KM; Olopade, OI; Olson, JE; Olsson, H; Osorio, A; Ottini, L; Park-Simon, T-W; Parsons, MT; Pedersen, IS; Peshkin, B; Peterlongo, P; Peto, J; Pharoah, PDP; Phillips, K-A; Polley, EC; Poppe, B; Presneau, N; Pujana, MA; Punie, K; Radice, P; Rantala, J; Rashid, MU; Rennert, G; Rennert, HS; Robson, M; Romero, A; Rossing, M; Saloustros, E; Sandler, DP; Santella, R; Scheuner, MT; Schmidt, MK; Schmidt, G; Scott, C; Sharma, P; Soucy, P; Southey, MC; Spinelli, JJ; Steinsnyder, Z; Stone, J; Stoppa-Lyonnet, D; Swerdlow, A; Tamimi, RM; Tapper, WJ; Taylor, JA; Terry, MB; Teulé, A; Thull, DL; Tischkowitz, M; Toland, AE; Torres, D; Trainer, AH; Truong, T; Tung, N; Vachon, CM; Vega, A; Vijai, J; Wang, Q; Wappenschmidt, B; Weinberg, CR; Weitzel, JN; Wendt, C; Wolk, A; Yadav, S; Yang, XR; Yannoukakos, D; Zheng, W; Ziogas, A; Zorn, KK; Park, SK; Thomassen, M; Offit, K; Schmutzler, RK; Couch, FJ; Simard, J; Chenevix-Trench, G; Easton, DF; Andrieu, N; Antoniou, AC (2021-02-17)
      Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in ...

    • A causal mechanism for childhood acute lymphoblastic leukaemia. 

      Greaves, M (2018-08)
      In this Review, I present evidence supporting a multifactorial causation of childhood acute lymphoblastic leukaemia (ALL), a major subtype of paediatric cancer. ALL evolves in two discrete steps. First, in utero initiation ...

    • A caveolin-dependent and PI3K/AKT-independent role of PTEN in beta-catenin transcriptional activity 

      Pendersen, Malin; Pedersen, Malin (2015-08)
      Loss of the tumour suppressor PTEN is frequent in human melanoma, results in MAPK activation, suppresses senescence and mediates metastatic behaviour. How PTEN loss mediates these effects is unknown. Here we show that loss ...

    • A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2. 

      Bery, N; Bataille, CJR; Russell, A; Hayes, A; Raynaud, F; Milhas, S; Anand, S; Tulmin, H; Miller, A; Rabbitts, TH (2021-04-09)
      Intracellular antibodies are tools that can be used directly for target validation by interfering with properties like protein-protein interactions. An alternative use of intracellular antibodies in drug discovery is ...

    • A cellular automaton model for spheroid response to radiation and hyperthermia treatments. 

      Brüningk, SC; Ziegenhein, P; Rivens, I; Oelfke, U; Haar, GT (2019-11-27)
      Thermo-radiosensitisation is a promising approach for treatment of radio-resistant tumours such as those containing hypoxic subregions. Response prediction and treatment planning should account for tumour response ...

    • A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. 

      Cook, G; Royle, K-L; Pawlyn, C; Hockaday, A; Shah, V; Kaiser, MF; Brown, SR; Gregory, WM; Child, JA; Davies, FE; Morgan, GJ; Cairns, DA; Jackson, GH (2019-03)
      Background Tolerability of treatments for multiple myeloma can depend on the characteristics of the patient being treated. We aimed to develop and validate a risk profile, using routinely collected data, that could predict ...

    • A clinical, molecular genetics and pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene 

      Olszewska, DA; Fearon, C; McGuigan, C; McVeigh, TP; Houlden, H; Polke, JM; Lawlor, B; Coen, R; Hutchinson, M; Hutton, M; Beausang, A; Delon, I; Brett, F; Sevastou, I; Seto-Salvia, N; de Silva, R; Lynch, T

    • A closed conformation of the Caenorhabditis elegans separase-securin complex. 

      Bachmann, G; Richards, MW; Winter, A; Beuron, F; Morris, E; Bayliss, R (2016-04-13)
      The protease separase plays a key role in sister chromatid disjunction and centriole disengagement. To maintain genomic stability, separase activity is strictly regulated by binding of an inhibitory protein, securin. Despite ...

    • A commercial antibody to the human condensin II subunit NCAPH2 cross-reacts with a SWI/SNF complex component 

      Cutts, E; Taylor, G; Pardo, M; Yu, L; Wills, J; Choudhary, J; Vannini, A; Wood, A (2021-01-13)
      Condensin complexes compact and disentangle chromosomes in preparation for cell division. Commercially available antibodies raised against condensin subunits have been widely used to characterise their cellular interactome. ...